McKinsey & Company

The Next Era of Healthcare Is Personal

The Mackenzie podcast episode spotlights Madna’s vision of a personal, information‑driven healthcare era. CEO Stefan Benell explains how the company’s mRNA platform treats DNA as an information molecule, allowing rapid design of vaccines, cancer immunotherapies, and treatments for rare genetic diseases. Key insights include the ability to shrink drug development timelines by integrating AI, real‑time project management, and a unified manufacturing process. Madna’s approach replaces the traditional ten‑year drug pipeline with a modular system where changing a genetic code yields a new therapeutic, and regulatory approval now focuses on validating the production process rather than each individual molecule. Benell cites a 50% improvement in five‑year survival for an individualized melanoma therapy and notes that phase‑three trials involving over a thousand patients are underway. The company has already launched flu and flu‑COVID combo vaccines and is expanding manufacturing capacity in Canada, the UK, and Australia, offering governments a flexible, on‑demand production tool. The implications are profound: personalized immunotherapies could dramatically increase response rates while reducing wasted drug spend, and a globally distributed, adaptable manufacturing network promises faster pandemic response and lower overall healthcare costs.